Candel Therapeutics shares surge 12.33% after-hours after announcing virtual R&D event on December 5, 2025.

Candel Therapeutics (CADL) surged 12.33% in after-hours trading following multiple positive developments. The stock’s rally aligns with recent announcements, including the company’s third-quarter 2025 financial results, a virtual R&D event scheduled for December 5, 2025, and interim data from its phase 1b CAN-3110 trial showing promise in recurrent glioblastoma. Additional catalysts included a $130 million term loan facility with Trinity Capital and appointments of leading immunology experts to its advisory board. These updates, coupled with presentations at major conferences like SITC 2025 and ASTRO 2025, reinforced investor confidence in Candel’s pipeline of viral immunotherapies and clinical advancements. The after-hours jump reflects optimism over its strategic partnerships, capital raising, and progress in next-generation cancer treatments.